EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases

Christian Hölscher

Frontiers in Synaptic Neuroscience · 27.07.2022 · 14

DOI: 10.3389/fnsyn.2022.955258 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Synaptic Neuroscience, online erschienen am 27.07.2022. Verfasst von Christian Hölscher. Beteiligte Einrichtung: Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are peptide hormones and growth factors. A major pathological feature of both Alzheimer’s dis-ease (AD) and Parkinson’s disease (PD) is the loss of synaptic transmission in the cortex in AD and the loss of dopaminergic synapses in the nigra-striatal dopaminergic projection. Several studies demonstrate that GLP-1 and GIP receptor agonists protect synapses and synaptic transmission from the toxic events that underlie AD and PD. In a range of AD animal models, treatment with GLP-1, GIP, or dual-GLP-1/GIP receptor agonists effectively protected cognition, synaptic trans-mission, long-term potentiation (LTP), and prevented the loss of synapses and neurons. In PD models, dopaminergic production resumed and synapses became functional again. Importantly, the GLP-1 receptor agonists exendin-4 and liraglutide have shown good protective effects in clinical trials in AD and PD patients. Studies show that growth factors and peptide drugs that can cross the blood–brain barrier (BBB) better are more potent than those that do not cross the BBB. We therefore developed dual-GLP-1/GIP receptor agonists that can cross the BBB at an enhanced rate and showed superior protective properties on synapses in animal models of AD and PD.

Schlagwörter

Stichwörter der Autor:innen

CNSLTPcognitiongrowth factorincretinsinsulinoxidative stresssynaptic plasticity

Autor:innen und Institutionen

  • Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.

Zitieren

APA

Hölscher, C. (2022). Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases. Frontiers in Synaptic Neuroscience, 14. https://doi.org/10.3389/fnsyn.2022.955258

Vancouver

Hölscher C. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases. Frontiers in Synaptic Neuroscience. 2022;14. doi:10.3389/fnsyn.2022.955258

BibTeX
@article{Hlscher2022,
  author = {Hölscher, Christian},
  title = {Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases},
  journal = {Frontiers in Synaptic Neuroscience},
  year = {2022},
  volume = {14},
  doi = {10.3389/fnsyn.2022.955258}
}
Kostenlos starten →